EGFR and neoplasm: All 4 radioimmunoconjugates demonstrated strong EGFR-specific targeting, with increasing tumor uptake over 15 d and reduced uptake on blocking (Fig. 4B; Supplemental Figs. 4–7; Supplemental Table 3).